对死后人脑中线粒体 DNA 改变的综合总结:系统评价。

Comprehensive summary of mitochondrial DNA alterations in the postmortem human brain: A systematic review.

机构信息

Research Department, Hospital Universitari Institut Pere Mata (HUIPM); Institut d'Investigació Sanitària Pere Virgili (IISPV); Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili (URV), 43201 Reus, Catalonia, Spain; Biomedical Network Research Centre on Mental Health (CIBERSAM), 28029 Madrid, Spain.

Laboratory of Muscle Research and Mitochondrial Function, Department of Internal Medicine-Hospital Clínic of Barcelona (HCB); Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB), 08036 Barcelona, Catalonia, Spain; Biomedical Network Research Centre on Rare Diseases (CIBERER), 28029 Madrid, Spain.

出版信息

EBioMedicine. 2022 Feb;76:103815. doi: 10.1016/j.ebiom.2022.103815. Epub 2022 Jan 24.

Abstract

BACKGROUND

Mitochondrial DNA (mtDNA) encodes 37 genes necessary for synthesizing 13 essential subunits of the oxidative phosphorylation system. mtDNA alterations are known to cause mitochondrial disease (MitD), a clinically heterogeneous group of disorders that often present with neuropsychiatric symptoms. Understanding the nature and frequency of mtDNA alterations in health and disease could be a cornerstone in disentangling the relationship between biochemical findings and clinical symptoms of brain disorders. This systematic review aimed to summarize the mtDNA alterations in human brain tissue reported to date that have implications for further research on the pathophysiological significance of mtDNA alterations in brain functioning.

METHODS

We searched the PubMed and Embase databases using distinct terms related to postmortem human brain and mtDNA up to June 10, 2021. Reports were eligible if they were empirical studies analysing mtDNA in postmortem human brains.

FINDINGS

A total of 158 of 637 studies fulfilled the inclusion criteria and were clustered into the following groups: MitD (48 entries), neurological diseases (NeuD, 55 entries), psychiatric diseases (PsyD, 15 entries), a miscellaneous group with controls and other clinical diseases (5 entries), ageing (20 entries), and technical issues (5 entries). Ten entries were ascribed to more than one group. Pathogenic single nucleotide variants (pSNVs), both homo- or heteroplasmic variants, have been widely reported in MitD, with heteroplasmy levels varying among brain regions; however, pSNVs are rarer in NeuD, PsyD and ageing. A lower mtDNA copy number (CN) in disease was described in most, but not all, of the identified studies. mtDNA deletions were identified in individuals in the four clinical categories and ageing. Notably, brain samples showed significantly more mtDNA deletions and at higher heteroplasmy percentages than blood samples, and several of the deletions present in the brain were not detected in the blood. Finally, mtDNA heteroplasmy, mtDNA CN and the deletion levels varied depending on the brain region studied.

INTERPRETATION

mtDNA alterations are well known to affect human tissues, including the brain. In general, we found that studies of MitD, NeuD, PsyD, and ageing were highly variable in terms of the type of disease or ageing process investigated, number of screened individuals, studied brain regions and technology used. In NeuD and PsyD, no particular type of mtDNA alteration could be unequivocally assigned to any specific disease or diagnostic group. However, the presence of mtDNA deletions and mtDNA CN variation imply a role for mtDNA in NeuD and PsyD. Heteroplasmy levels and threshold effects, affected brain regions, and mitotic segregation patterns of mtDNA alterations may be involved in the complex inheritance of NeuD and PsyD and in the ageing process. Therefore, more information is needed regarding the type of mtDNA alteration, the affected brain regions, the heteroplasmy levels, and their relationship with clinical phenotypes and the ageing process.

FUNDING

Hospital Universitari Institut Pere Mata; Institut d'Investigació Sanitària Pere Virgili; Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (PI18/00514).

摘要

背景

线粒体 DNA(mtDNA)编码了合成氧化磷酸化系统 13 个必需亚基所必需的 37 个基因。mtDNA 改变已知会导致线粒体疾病(MitD),这是一组临床上具有异质性的疾病,通常表现出神经精神症状。了解 mtDNA 改变在健康和疾病中的性质和频率可能是阐明生物化学发现与脑疾病临床症状之间关系的基石。本系统综述旨在总结迄今为止报告的与 mtDNA 改变有关的人类脑组织改变,这些改变对进一步研究 mtDNA 改变在大脑功能中的病理生理意义具有重要意义。

方法

我们使用与死后人类大脑和 mtDNA 相关的不同术语,在 PubMed 和 Embase 数据库中进行了搜索,截至 2021 年 6 月 10 日。如果研究报告是对死后人类大脑中的 mtDNA 进行的经验性研究,则符合纳入标准。

发现

共有 637 项研究中的 158 项符合纳入标准,并分为以下几组:MitD(48 项)、神经疾病(NeuD,55 项)、精神疾病(PsyD,15 项)、具有对照和其他临床疾病的杂项组(5 项)、衰老(20 项)和技术问题(5 项)。有 10 项归入了一个以上的组别。致病性单核苷酸变异(pSNVs),无论是同质或异质变体,在 MitD 中广泛报道,异质体水平在不同脑区之间存在差异;然而,在 NeuD、PsyD 和衰老中 pSNVs 较少见。大多数(但并非全部)已确定的研究都描述了疾病中的 mtDNA 拷贝数(CN)降低。在四个临床类别和衰老中都发现了 mtDNA 缺失。值得注意的是,与血液样本相比,脑组织样本中的 mtDNA 缺失和更高的异质体百分比更为明显,并且大脑中存在的一些缺失在血液中未被检测到。最后,mtDNA 异质体、mtDNA CN 和缺失水平取决于所研究的脑区。

解释

mtDNA 改变已知会影响包括大脑在内的人类组织。一般来说,我们发现 MitD、NeuD、PsyD 和衰老的研究在研究的疾病或衰老过程的类型、筛选的个体数量、研究的脑区和使用的技术方面存在很大差异。在 NeuD 和 PsyD 中,不能明确将任何特定类型的 mtDNA 改变归因于任何特定的疾病或诊断组。然而,mtDNA 缺失和 mtDNA CN 变化的存在意味着 mtDNA 在 NeuD 和 PsyD 中发挥作用。异质体水平和阈值效应、受影响的脑区以及 mtDNA 改变的有丝分裂分离模式可能与 NeuD 和 PsyD 的复杂遗传以及衰老过程有关。因此,需要更多关于 mtDNA 改变的类型、受影响的脑区、异质体水平及其与临床表型和衰老过程的关系的信息。

资助

Hospital Universitari Institut Pere Mata;Institut d'Investigació Sanitària Pere Virgili;Instituto de Salud Carlos III,Ministerio de Ciencia e Innovación(PI18/00514)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f769/8790490/5faafc50378b/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索